Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach DOI
Miguel López de Rodas, María Villalba, Miguel F. Sanmamed

et al.

Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

Language: Английский

T cells in health and disease DOI Creative Commons
Lina Sun, Yanhong Su, Anjun Jiao

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: June 19, 2023

T cells are crucial for immune functions to maintain health and prevent disease. cell development occurs in a stepwise process the thymus mainly generates CD4

Language: Английский

Citations

359

Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses DOI Creative Commons
Can Cui, Jiawei Wang, Eric Fagerberg

et al.

Cell, Journal Year: 2021, Volume and Issue: 184(25), P. 6101 - 6118.e13

Published: Nov. 30, 2021

Language: Английский

Citations

311

The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes DOI Creative Commons

Qizhao Huang,

Xia Wu, Zhiming Wang

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(22), P. 4049 - 4066.e25

Published: Oct. 1, 2022

Language: Английский

Citations

248

Dynamics and specificities of T cells in cancer immunotherapy DOI
Giacomo Oliveira, Catherine J. Wu

Nature reviews. Cancer, Journal Year: 2023, Volume and Issue: 23(5), P. 295 - 316

Published: April 12, 2023

Language: Английский

Citations

240

Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes DOI Creative Commons
Maha K. Rahim, Trine Line Hauge Okholm, Kyle B. Jones

et al.

Cell, Journal Year: 2023, Volume and Issue: 186(6), P. 1127 - 1143.e18

Published: March 1, 2023

CD8

Language: Английский

Citations

218

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor DOI Creative Commons

Nataliya Prokhnevska,

Maria A. Cardenas,

Rajesh M. Valanparambil

et al.

Immunity, Journal Year: 2022, Volume and Issue: 56(1), P. 107 - 124.e5

Published: Dec. 28, 2022

Language: Английский

Citations

193

Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade DOI
Baolin Liu, Yuanyuan Zhang, Dongfang Wang

et al.

Nature Cancer, Journal Year: 2022, Volume and Issue: 3(9), P. 1123 - 1136

Published: Sept. 22, 2022

Language: Английский

Citations

172

CD8+ T cells in the cancer-immunity cycle DOI Creative Commons
Josephine R. Giles, Anna-Maria Globig,

Susan M. Kaech

et al.

Immunity, Journal Year: 2023, Volume and Issue: 56(10), P. 2231 - 2253

Published: Oct. 1, 2023

Language: Английский

Citations

161

‘Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responses DOI Open Access
Dietmar Zehn, Robert Thimme, Enrico Lugli

et al.

Nature Immunology, Journal Year: 2022, Volume and Issue: 23(6), P. 836 - 847

Published: May 27, 2022

Language: Английский

Citations

121

Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy DOI Open Access
Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha

et al.

Immune Network, Journal Year: 2022, Volume and Issue: 22(1)

Published: Jan. 1, 2022

Targeting immune evasion via checkpoint pathways has changed the treatment paradigm in cancer. Since CTLA-4 antibody was first approved 2011 for of metastatic melanoma, eight inhibitors (ICIs) centered on PD-1 pathway blockade are and currently administered to treat 18 different types cancers. The part review focuses history discovery preclinical experiments that demonstrated possibility anti-CTLA-4 anti-PD-1 as anti-cancer therapeutics. approval process clinical trials utility ICIs described, specifically focusing non-small cell lung cancer (NSCLC), which immunotherapies most actively applied. Additionally, this covers combination therapy novel under investigation NSCLC. Although now key pivotal option settings, they show inconsistent therapeutic efficacy limited responsiveness. Thus, newly proposed action mechanism overcome limitations a near future also discussed.

Language: Английский

Citations

115